company background image
VERU

Veru NasdaqCM:VERU Stock Report

Last Price

US$5.47

Market Cap

US$441.0m

7D

-0.5%

1Y

-12.5%

Updated

10 Dec, 2022

Data

Company Financials +
VERU fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

VERU Stock Overview

Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of COVID-19, and breast and prostate cancers.

Veru Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Veru
Historical stock prices
Current Share PriceUS$5.47
52 Week HighUS$24.55
52 Week LowUS$4.34
Beta-0.33
1 Month Change-63.56%
3 Month Change-64.87%
1 Year Change-12.48%
3 Year Change126.97%
5 Year Change341.13%
Change since IPO-17.43%

Recent News & Updates

Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Nov 13
Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Recent updates

Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Nov 13
Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?

Sep 26
Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?

Is Veru (NASDAQ:VERU) Using Debt Sensibly?

May 25
Is Veru (NASDAQ:VERU) Using Debt Sensibly?

Newsflash: Veru Inc. (NASDAQ:VERU) Analysts Have Been Trimming Their Revenue Forecasts

Feb 11
Newsflash: Veru Inc. (NASDAQ:VERU) Analysts Have Been Trimming Their Revenue Forecasts

Health Check: How Prudently Does Veru (NASDAQ:VERU) Use Debt?

Nov 15
Health Check: How Prudently Does Veru (NASDAQ:VERU) Use Debt?

We Take A Look At Whether Veru Inc.'s (NASDAQ:VERU) CEO May Be Underpaid

Mar 17
We Take A Look At Whether Veru Inc.'s (NASDAQ:VERU) CEO May Be Underpaid

Shareholders In Veru (NASDAQ:VERU) Should Look Beyond Earnings For The Full Story

Feb 23
Shareholders In Veru (NASDAQ:VERU) Should Look Beyond Earnings For The Full Story

News Flash: Analysts Just Made An Incredible Upgrade To Their Veru Inc. (NASDAQ:VERU) Forecasts

Feb 17
News Flash: Analysts Just Made An Incredible Upgrade To Their Veru Inc. (NASDAQ:VERU) Forecasts

Here's Why Veru (NASDAQ:VERU) Can Manage Its Debt Responsibly

Feb 16
Here's Why Veru (NASDAQ:VERU) Can Manage Its Debt Responsibly

If You Had Bought Veru (NASDAQ:VERU) Stock Three Years Ago, You Could Pocket A 617% Gain Today

Jan 27
If You Had Bought Veru (NASDAQ:VERU) Stock Three Years Ago, You Could Pocket A 617% Gain Today

Breakeven On The Horizon For Veru Inc. (NASDAQ:VERU)

Jan 05
Breakeven On The Horizon For Veru Inc. (NASDAQ:VERU)

What Kind Of Investors Own Most Of Veru Inc. (NASDAQ:VERU)?

Dec 15
What Kind Of Investors Own Most Of Veru Inc. (NASDAQ:VERU)?

Shareholder Returns

VERUUS Personal ProductsUS Market
7D-0.5%-0.6%-3.6%
1Y-12.5%-36.4%-20.6%

Return vs Industry: VERU exceeded the US Personal Products industry which returned -34.9% over the past year.

Return vs Market: VERU exceeded the US Market which returned -19.6% over the past year.

Price Volatility

Is VERU's price volatile compared to industry and market?
VERU volatility
VERU Average Weekly Movement21.9%
Personal Products Industry Average Movement10.7%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: VERU is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.

Volatility Over Time: VERU's weekly volatility has decreased from 33% to 22% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1971233Mitch Steinerhttps://www.verupharma.com

Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of COVID-19, and breast and prostate cancers. Its commercial products comprise FC2 female condom/internal condom for the protection against unintended pregnancy and the transmission of sexually transmitted infections; and Entadfi, a capsule for the treatment of urinary tract symptoms. The company’s drug candidates under development include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase 2b clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer.

Veru Inc. Fundamentals Summary

How do Veru's earnings and revenue compare to its market cap?
VERU fundamental statistics
Market CapUS$441.01m
Earnings (TTM)-US$83.78m
Revenue (TTM)US$39.35m

11.2x

P/S Ratio

-5.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VERU income statement (TTM)
RevenueUS$39.35m
Cost of RevenueUS$8.76m
Gross ProfitUS$30.59m
Other ExpensesUS$114.37m
Earnings-US$83.78m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.04
Gross Margin77.73%
Net Profit Margin-212.88%
Debt/Equity Ratio13.4%

How did VERU perform over the long term?

See historical performance and comparison